![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
JE Shook, JT Pelton, VJ Hruby and TF Burks
Department of Pharmacology, University of Arizona, Tucson.
The purpose of these investigations was to determine 1) whether peripherally located mu, delta and kappa opioid receptors can inhibit the rate of gastrointestinal transit and, if so, 2) do peripheral opioid receptors mediate the constipation caused by systemic morphine? and 3) whether constipation can be separated from analgesia on the basis of different sites of action. We studied the effects of peripherally administered (s.c.) mu, delta and kappa opioid receptor selective agonists on the rate of gastrointestinal transit in mice. We used peptidergic agonists with high peripheral selectivity (limited ability to cross the blood-brain barrier) including [MePhe3,D- Pro4]morphiceptin (PL017) (mu), [D-Pen2,D-Pen5]enkephalin (DPDPE) (delta) and Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg (dynorphin 1-9) (kappa). As peripheral selectivity is dose-related, we included the hot- plate test as an index of that dose at which each compound lost its peripheral selectivity and entered the central nervous system. When given s.c., [MePhe3,D-Pro4]morphiceptin inhibited transit (IC50 = 0.37 mg/kg s.c.) at doses much lower than those needed to produce analgesia (A50 = 30 mg/kg s.c.), indicating that peripheral mu receptors can inhibit transit independently of central mu receptors. The independence of peripheral mu antitransit receptors from central receptors was demonstrated further as the lack of antagonism of s.c. [MePhe3,D- Pro4]morphiceptin antitransit effects by simultaneous i.c.v. administration of the mu receptor antagonist D-Phe-Cys-Tyr-D-Trp-Lys- Thr-Pen-Thr-NH2 (CTP) (1 microgram i.c.v.).(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  A. Zhao, M. Morimoto, H. Dawson, J. E. Elfrey, K. B. Madden, W. C. Gause, B. Min, F. D. Finkelman, J. F. Urban Jr, and T. Shea-Donohue Immune Regulation of Protease-Activated Receptor-1 Expression in Murine Small Intestine during Nippostrongylus brasiliensis Infection J. Immunol., August 15, 2005; 175(4): 2563 - 2569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-S. Yuan, H. Doshan, M. R. Charney, M. O'Connor, T. Karrison, S. A. Maleckar, R. J. Israel, and J. Moss Tolerability, Gut Effects, and Pharmacokinetics of Methylnaltrexone Following Repeated Intravenous Administration in Humans J. Clin. Pharmacol., May 1, 2005; 45(5): 538 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. N. Sterious and E. A. Walker Potency Differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an Antagonist of Peptide and Alkaloid {micro}-Agonists in an Antinociception Assay J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 301 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Witt, J. D. Huber, R. D. Egleton, M. J. Roberts, M. D. Bentley, L. Guo, H. Wei, H. I. Yamamura, and T. P. Davis Pharmacodynamic and Pharmacokinetic Characterization of Poly(Ethylene glycol) Conjugation to Met-Enkephalin Analog [D-Pen2,D-Pen5]-enkephalin (DPDPE) J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 848 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Valle, O. Pol, and M. M. Puig Intestinal Inflammation Enhances the Inhibitory Effects of Opioids on Intestinal Permeability in Mice J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 378 - 387. [Abstract] [Full Text]
|
|
|
|
|
|
M. M. Puig and O. Pol Peripheral Effects of Opioids in a Model of Chronic Intestinal Inflammation in Mice J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 1068 - 1075. [Abstract] [Full Text]
|
|
|
|
|
|
S. A. Thomas, T. J. Abbruscato, V. S. Hau, T. J. Gillespie, J. Zsigo, V. J. Hruby, and T. P. Davis Structure-Activity Relationships of a Series of [D-Ala2]Deltorphin I and II Analogues; in Vitro Blood-Brain Barrier Permeability and Stability J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 817 - 825. [Abstract] [Full Text]
|
|
|
|
|
|
S. A. Thomas, T. J. Abbruscato, V. J. Hruby, and T. P. Davis The Entry of [D-Penicillamine2,5]Enkephalin into the Central Nervous System: Saturation Kinetics and Specificity J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1235 - 1240. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
